News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Jiangsu Hengrui Medicine Co. Ltd. Reports Positive Phase 3 Data For Cancer Drug


6/4/2014 10:36:13 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

by Richard Daverman, PhD

June 3, 2014 -- Jiangsu Hengrui Medicine announced that apatinib, its oral treatment for metastatic gastric cancer, successfully completed a Phase III trial in China. Data from the trial were presented at the recent ASCO conference in Chicago, and the presentation was included as a Best of ASCO selection. Hengrui has filed with the CFDA for marketing approval of apatinib in China. More details....

Stock Symbol: (SHA: 600276)

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES